Wereport a case of cerebral aspergillosis which originated from the sphenoid sinus, and involved a progressive decrease of visual acuity. The neurological signs indicated a cavernous sinus invasion. After extensive intracranial surgery we treated the residual aspergillosis with a high oral dose of itraconazole (800 mg/d for 4 months, followed by 400 mg/d for 5 months). The neurological impairments of the patient gradually subsided with the resolution of the fungal lesion shown on MRI. The successful therapy indicated that itraconazole has a significant role in the treatment of advanced cerebral aspergillosis if it is used in high doses (16 mg/kg/d for adults).
Introduction
Cerebral aspergillosis due to a primary infection of the nasal sinuses is commonin hot and dry areas such as the Sudan, but it is rare in Japan (1, 2) . This form of cerebral aspergillus infection has a very poor prognosis in spite of intracranial surgery and conventional antifungal therapy. Recent reviews suggest that high-dose itraconazole (ITZ) is a suitable treatment for cerebral aspergillosis (3) . Wereport a case of a skull base aspergillus infection which originated from the sphenoid sinus. It was successfully treated with high-dose ITZ.
Case Reports
In September 1996 a 47-year-old man with a history of poorly controlled diabetes mellitus was admitted to the Department of Ophthalmology in our hospital. He presented with a loss of left visual acuity which had developed in 1 month. Following a tentative diagnosis of optic neuritis, he received high doses of intravenous corticosteroids as a treatment. However subsequent cranial computed tomography (CT) showed an enhanced lesion in the left sphenoid sinus and also the left optic canal. An external sphenoidectomy was performed and a thick pasty material was aspirated. Whenthe aspirated material was examined microscopically numerous aspergilli were evident. The treatment was then changed to intravenous fluconazole (FLCZ) at 200 mg/d (equivalent to 2 mg/kg of body weight) for 1 week, and then increased to 600 mg/d (equivalent to 12 mg/kg of body weight) for the next 2 weeks, but no clinical improvementwas observed. Cranial magnetic resonance imaging (MRI; GE Signa 1.5 tesla system) of the patient revealed a direct extension of the lesion from the left sphenoid sinus to the left frontal lobe ( Fig. 1 and 2A) . The patient was transferred to the Department of Neurology in October 1996. On admission he complained of a dull pain in the left frontal area which subsided after nonsteroidal anti-inflammatory drug administration. The patient was afebrile, completely conscious and well-orientated, but blind in the left eye with a MarcusGunnpupil. Neither extraocular muscle weaknessnor ptosis were observed. Theother cranial nerves and the cerebellum were intact and abnormalities in the trunk and limbs were not detected. The results of routine hematological and biochemical investigations were within normal limits. The erythrocyte sedimentation rate was normal, and the result of a test for Creactive protein was negative. The total protein and cell count in the CSF were 65 mg/dl, and 1 lymphocyte and 2 neutrocytes per mm3,respectively. The patient's diabetes mellitus was controlled by insulin therapy and repeat electroencephalograms indicated the absence of any abnormality. After admission he developed ptosis and weak extraocular muscles due to a left oculomotor palsy, but he did not complain of double vision (due to left blindness). intensity-enhanced cyst at the frontal lobe base ( Fig. 2A and B) were consistently shown in serial cranial MRIs. Dueto a sudden increase in headaches in the left forehead and decreased visual acuity of the right eye, he returned to our department in February 1997. Cranial CTscans revealed a new fungal lesion which had expanded beyond the midline to the right optic canal and involved the right optic nerve. The CT scans did not reveal a granulomatous lesion or fluid retention within the right sphenoid and ethmoid sinuses. On the basis of these findings, we concluded that the sudden loss of right visual acuity was probably caused by constriction of the optic nerve by the granulomatous aspergillus lesion within the right optic canal.
A right frontotemporal craniotomy was immediately performed to decompress the right optic nerve. It was observed that the dura over the medial part of the right pterion, tuberculum sella and planum sphenoidale was covered with a thick, soft and grayish-granulomatous tissue. The lesion around the right optic nerve was removed meticulously and the roof of the right optic canal wasalso removedso that the optic nerve was sufficiently decompressed. Although cranial MRIs demonstrated an aspergillus brain abscess in the deep medial frontal Cerebral Aspergillosis lobe ( Fig. 2A and B) , excisional surgery did not approach the abscess so that the dura remained intact. A histopathological examination of the resected tissue showedthe presence of aspergillus hyphae with reactive inflammatory cells. Mucormycosis, which is more commonin poorly controlled diabetes mellitus (4), was not present in the tissue. His visual acuity and right eye movements recovered immediately after the excisional surgery. The dose of ITZ was increased to 600 mg/d (equivalent to 12 mg/kg of body weight) for the next 4 weeks, and then to 800 mg/d (equivalent to 16 mg/kg of body weight). The serum concentration of the antifungal drugs, measured by high power liquid chromatography (Fig. 2C) nor thickening of the adjacent dura (Fig. 2D ) and the cavernous sinus was not enhanced. The patient developed facial pigmentation, eruption of the skin on the upper limbs and trunk, and postural hand tremor during high therapeutic doses of ITZ. Laboratory findings revealed a moderate serum ACTH elevation at 800 mg/d ITZ. All these changes were side effects due to the high dose of ITZ. The skin changes and postural hand tremor eventually disappeared, and the serum ACTHlevel returned to normal when the dose was reduced.
Discussion
Invasive aspergillosis is usually either a serious complication of immunosuppressive treatment or diseases which profoundly impair normal immunity. Aspergillus infection has been noted in almost every organ and system of the human body (6) . Involvement of the lung, sinus, bone and brain was relatively commonin the review of 2,121 published cases with invasive aspergillosis (6) . Histologically, 20 of 32 necropsies of invasive aspergillosis showed a wide range beyond the lungs, with the brain being the most commonsite (7). Invasive aspergillosis from the sinuses into the skull base often affects the orbits, the cavernous sinuses, and involves the cranial nerves. In an advanced stage it causes carotid arteritis, carotid occlusion, meningitis and brain abscesses. The mortality rate is very high in the advanced condition (2). At present, there is no completely effective treatment for aspergillus brain abscesses. Aspergillus abscesses with capsules are often surgically drained or removed, depending on the size and location of a lesion, yet this is rarely curative. Any successful outcome in the reported cases with cerebral aspergillosis can be attributed to a combination of aggressive surgery supplemented by the use of antifugal drugs, including ITZ (8) . Amphotericin B is the only antifungal agent licensed in the United States of America for the treatment of aspergillosis (9) . The side effects of this agent frequently include febrile reactions and nephrotoxicity (10) , and its efficacy is said to be suboptimal (9) . To attain a significantly higher tissue level with less toxicity than conventional amphotericin B (8), a lipid formulation of amphotericin B has been recommended as the firstline therapy for cerebral aspergillosis. However this drug has not been available in Japan. A significant efficacy of miconazole and FLCZfor human aspergillus infections (6) has not been demonstrated. Indeed in the present case, even at high doses, FLCZdid not prevent progression of the disease. Itraconazole is a triazole derivative with a broad antifungal spectrum which includes the aspergillus species (1 1-13); it is been available as an oral preparation. Its distribution in human tissues has been studied after single or repeated oral administrations of 100 mg or 200 mg (14) . Although concentrations of ITZ were below 1-2 ng/ml in most body fluids, the tissue concentrations of ITZ were much higher, indicating extensive distribution of the drug to the tissues. In humans neither the brain nor meningeal concentration has been determined, however in dogs, during long-term administration the amount of the drug at either site was slightly more than that in the plasma (14) . In general ITZ appears to be tolerated well (15) and most of the reported adverse reactions are transient. Gastrointestinal reactions, mild dyspepsia, heart burn, nausea, vomiting, diarrhea and epigastric pain are not uncommon. Administration of high doses gives rise to an increased incidence of side effects: among those documented are severe hypokalemia, reversible adrenal insufficiency and arrythmias. The latter is connected with an interaction with terfenadine. Skin rashes and pruritus have also been reported as hypersensitivity reactions ( 1 5). Consequently it is necessary to watch for possible side effects, and to monitor serum concentrations of ITZ during high dose administration. The bioassay technique employed in the present study measured both ITZ and its major active metabolite, hydroxy-ITZ (16) . There are no defined concentrations of ITZ and hydroxy-ITZ that consistently yield a predictable and favorable response against invasive aspergillosis (9) . In general, however, higher concentrations appear to be desirable. Recent reports have recommendedthe use of high dose ITZ for highrisk patients with cerebral aspergillosis for whomconventional therapy has failed (3, 17) . On the basis of our experience, we strongly recommend high doses of ITZ combined (if necessary) with radical surgery for the treatment of advanced cerebral aspergillosis.
